Syndax Pharmaceuticals Inc. announced preliminary, unaudited financial results for the fourth quarter and full year 2025 ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference. The company reported approximately $44 million in Revuforj® (revumenib) net revenue for the fourth quarter and $125 million for the full year 2025. Revuforj net revenue increased by approximately 38% in the fourth quarter compared to the third quarter, following its approval in relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). Niktimvo™ (axatilimab-csfr) generated preliminary net revenue of $56 million in the fourth quarter and $152 million for the full year 2025. Syndax stated it will report its share of Niktimvo net profit with its full year 2025 results. The company ended 2025 with approximately $394 million in cash, cash equivalents, and marketable securities (unaudited), and noted it is fully funded through profitability. Syndax also announced plans to initiate a clinical program in 2026 to generate proof-of-principle data for revumenib in myelofibrosis.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623489-en) on January 12, 2026, and is solely responsible for the information contained therein.
Comments